Good evening, everyone, and welcome to the Stocktwits Top 25 Newsletter for Week 9 in 2021.
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD), and tracks their performances over time.
Here are your Stocktwits Top 25 Lists for Week 9:
ST Top 25 S&P 500
The ST Top 25 S&P 500 led the 3 lists once again. 24 of 25 names closed higher.
Marathon Oil Corp. marched another 17% in back-to-back weeks. $MRO remains ranked #3.
$FANG flew 23% and is the List’s biggest Winner. It’s a Winner below.
The Stocktwits Top 25 S&P 500 Momentum Meter increased 10.78% while the S&P 500 gained 0.81%. The 9.97% differential indicates the top stocks performed much stronger than the full index.
The Big Cap Nasdaq 100
The ST Top 25 N100 List was the only list to close lower in Week 9. 17 of 25 names were red.
Fox Corp flew 17 spots higher, from #18 to #1. The mass media corporation gained 24%, see more below.
3 new names made the list.
The ST Top 25 Nasdaq 100 Momentum Meter decreased 0.25% during Week 9 while the full Nasdaq 100 moved 1.87% lower. The 1.62% differential suggests the top stocks performed a bit better than the full index.
Small-Cap Russell 2000
The ST Top 25 Russell 2000 was bounced back in Week 9. 14 names closed higher.
GameStop Corp is back and here to stay? The MemeStock gained 35.4% and stole the #1 spots on the ST Top 25 R2K List from Cassava Sciences.
Morphic Holding Inc moved 94% higher after reporting earnings. It’s ranked #23 and is the Top Dawg below.
9 new Freshmen appeared.
The ST Top 25 R2K Momentum Meter moved 10.90% higher while the Russell 2000 index fell 0.40%. The 11.30% differential suggests that the top stocks outperformed the full index bigly.
ST Top 25 TOP DAWG OF THE WEEK 🐶
The ST Top 25 Top Dawg for Week 9, 2021 is #23 R2K – Morphic Holding Corp.
Morphic Holding Corp. morphed into a monster in Week 9, gaining 94%. The stock opened 24% higher Monday at $45, it now trades at $70.05… $MORF is a Freshman and the 23rd ranked stock on the ST Top 25 R2K List.
Here’s the daily chart:
$MORF reported quarterly results on Monday, highlighting positive preliminary results from Phase 1 clinical trials on its MORF-057 inflammatory bowel disease medicine. Throughout testing, the drug was tolerated without any unfavorable effects.
Other highlights from the report include; receiving $20 million from AbbVie for exercise of a license option, expanding R&D with Janssen (a subsidiary of Johnson & Johnson), and advancing novel integrin-targeted candidates against integrins αvβ1 and αvβ8 for the treatment of fibrosis and cancer
Praveen Tipirneni, CEO of Morphic Therapeutic said:
Most notably in 2020, our lead oral candidate in IBD, MORF-057, completed preclinical testing with strong proof-of-concept and entered the clinic. In an important milestone for Morphic, we have already delivered positive preliminary results from the MORF-057 Phase 1 trial. The data show a favorable tolerability profile as well as strong pharmacodynamic data that suggest α4β7 inhibition may be on par with the approved intravenous blockbuster, vedolizumab.
$MORF is up 109% YTD.
The Winners 📈
△ #5 S&P 500 – Diamondback Energy led the energy-filled ST Top 25 S&P 500 List with a 24% gain. Diamondback gained 2 spots, moving from #7 to #5.
Here’s the daily chart of $FANG:
Can oil keep it up? Place your bets…
△ #1 N100 – Fox Corporation was the biggest gainer on the ST Top 25 N100 List, up 24%. The mass media company flew 17 spots from #18 to #1. Quite a move.
The catalyst of $FOXA’s incredible weekly gain was FOX News Channel finishing February as the top-rated network in all of cable in primetime, according to Nielsen Media Research. CNN’s ratings plummeted, forfeiting nearly 50% of its viewership versus the prior month.
Tucker Carlson Tonight, Hannity, and The Five were all ranked in the top five cable news programs in total viewers for February.
$FOXA sits just 1% away from all-time highs.
△ #17 R2K – Five Prime Therapeutics Inc flew 70% to close at 4-year highs. The biotech stock claimed the #17 spot on the ST Top 25 R2K List as a Freshman.
The acquisition allows Amgen an opportunity to strengthen its oncology portfolio with first-in-class global assets to treat gastric cancer.
Tom Civik, CEO of Five Prime said:
This is an exciting day for patients who may one day benefit from the promise of bemaritizumab and our full pipeline. I’m so proud of the Five Prime team and the science we’ve pioneered. We see tremendous complementarity between the two companies. Amgen has global reach, world-class resources, and they share our deep passion for science and commitment to patients. I have full confidence that Amgen is the right company to work with us to bring our innovative cancer treatments to patients and to achieve our mission to rewrite cancer.
Congrats on the exit, team. 👏
The Sinners 📉
▼ #24 N100 – Illumina Inc fell for the third straight week, closing back below $400. The biotech descended 9.25% and lost 13 spots on the ST Top 25 R2K List. It fell from #11 to #24.
$ILMN closed at all-timers in Week 6 and was highlighted as a Winner after beating earnings expectations. Since then, the stock has lost 21% and fallen 19 spots.
Here’s the weekly chart:
If there is any silver lining, it’s that Illumina received medical device registration in Russia for its NextSeq™ 550Dx platform and associated reagent kits on Friday. The registrations will allow for the expansion of sequencing-based clinical diagnostics across the country.
Paula Dowdy, Senior VP and GM of Illumina, Europe Middle East, and Africa said:
Having the two IVD-platforms available to assay developers to expand the clinical use of Next Generation Sequencing-based (NGS) molecular diagnostics will be a great boost to testing for genetic diseases and oncology in Russia.
▼ #12 R2K – 3D Systems Inc dropped 31% like it was hot in Week #9. The 3D printing company lost 4 spots, decreasing from #8 to #12 on the ST Top 25 R2K List.
$DDD reported delayed Q4 earnings after the close on Monday. The company missed on earnings but beat on revenue.
Here are the stats:
EPS: $0.09 vs $0.11 est.
Revenue: $172.65m, +5% YoY
3D Systems CEO, Dr. Jeff Graves said:
With our singular focus on additive manufacturing, we were pleased to deliver strong growth at the end of what was an unprecedented year. The execution of our four-stage plan to deliver increased value to our customers and shareholders, initiated in the summer of 2020, took hold and rapidly gained momentum as we moved through the second half of the year.
$DDD is still up 136% YTD.
▼ #24 S&P 500 – Tapestry Inc tumbled just 0.55% in Week 9 but was demoted 10 spots on the ST Top 25 List. The stock was the ugly duckling of the list being the only name to close red.
Despite the poor weekly close, $TPR is still up 35% YTD, and up ~ 300% from its low March close.